Gilead Sciences has gotten a crucial nod for its Vitekta treatment. The company announced that the European Commission -- the executive arm of the European Union -- has granted marketing authorization for the drug. The approval is for two doses, 85 milligrams and 150 milligrams, both of which are offered in tablet form.

Vitekta belongs to a class of treatments called integrase inhibitors and is used in combination with other compounds to suppress HIV. It works by interfering "with HIV replication by blocking the virus from integrating into the genetic material of human cells," in Gilead's words. The company added that in clinical trials, Vitekta effectively suppressed HIV in patients carrying drug-resistant strands of the virus.

In spite of the positive news, Gilead's stock price fell in the wake of the announcement. The shares dropped by 1.3%, or $0.92, to close the day at $68.97. 

The article Gilead's HIV-1 Drug Wins Approval in Europe originally appeared on Fool.com.

Fool contributor Eric Volkman has no position in Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Income Investing

Grow your nest-egg.

View Course »

Introduction to ETFs

The basics of Exchange Traded Funds and why ETFs are hot.

View Course »

Add a Comment

*0 / 3000 Character Maximum